HC Wainwright Has Negative Outlook of VolitionRx Q4 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

VolitionRx Limited (NYSE:VNRX - Free Report) - Investment analysts at HC Wainwright reduced their Q4 2025 EPS estimates for shares of VolitionRx in a research report issued to clients and investors on Monday, August 18th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $0.04 for the quarter, down from their previous estimate of $0.09. The consensus estimate for VolitionRx's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx's Q2 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.04 EPS.

Other equities research analysts have also recently issued reports about the company. D. Boral Capital restated a "buy" rating and set a $5.00 target price on shares of VolitionRx in a report on Friday. Wall Street Zen assumed coverage on VolitionRx in a research note on Thursday, May 15th. They set a "sell" rating for the company. Finally, Jones Trading upgraded shares of VolitionRx to a "strong-buy" rating and set a $3.00 target price on the stock in a report on Tuesday, June 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, VolitionRx has a consensus rating of "Moderate Buy" and a consensus target price of $3.50.

VolitionRx Stock Down 1.7%

NYSE VNRX opened at $0.68 on Tuesday. The company has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $0.59. VolitionRx has a 12-month low of $0.40 and a 12-month high of $0.94. The firm has a market cap of $71.03 million, a price-to-earnings ratio of -1.90 and a beta of 1.26.

Insider Activity at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 78,125 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average price of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the director directly owned 966,814 shares of the company's stock, valued at $618,760.96. The trade was a 8.79% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Cameron John Reynolds purchased 78,125 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the acquisition, the chief executive officer owned 2,609,847 shares of the company's stock, valued at $1,670,302.08. This represents a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 188,750 shares of company stock valued at $118,175. Company insiders own 10.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Lagoda Investment Management L.P. boosted its stake in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Armistice Capital LLC lifted its holdings in VolitionRx by 3.5% in the second quarter. Armistice Capital LLC now owns 8,493,074 shares of the company's stock worth $6,455,000 after buying an additional 286,644 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRx during the 2nd quarter valued at approximately $52,000. Millennium Management LLC purchased a new position in shares of VolitionRx during the 4th quarter worth approximately $36,000. Finally, Silverberg Bernstein Capital Management LLC grew its holdings in shares of VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after acquiring an additional 60,209 shares during the period. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.